Delstrigo is a prescription medication used to treat human immunodeficiency virus type 1 (HIV-1) infection in adults. It is a single tablet regimen containing three active ingredients: doravirine, lamivudine, and tenofovir disoproxil fumarate [1].
How does Delstrigo work?
Delstrigo is a combination antiretroviral therapy. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by preventing HIV from multiplying [1]. Lamivudine and tenofovir disoproxil fumarate are nucleoside reverse transcriptase inhibitors (NRTIs) that also interfere with HIV replication [1]. By combining these mechanisms, Delstrigo effectively reduces the amount of HIV in the body, allowing the immune system to strengthen [1].
What is the recommended dosage for Delstrigo?
The recommended dosage for Delstrigo is one tablet taken orally once daily [1]. It can be taken with or without food [1].
What are the potential side effects of Delstrigo?
Common side effects reported with Delstrigo include dizziness, nausea, headache, fatigue, and diarrhea [1]. More serious side effects can include new or worsening kidney problems, liver problems, and lactic acidosis [1]. Patients should consult with their healthcare provider about any potential side effects and their medical history [1].
What are the contraindications for Delstrigo?
Delstrigo should not be taken by patients who are taking dofetilide [1]. This is because Delstrigo can increase dofetilide levels, potentially leading to serious heart rhythm problems [1].
When does Delstrigo's patent expire?
Information regarding specific patent expiration dates for Delstrigo can be found on resources like DrugPatentWatch.com [2]. Patent exclusivity is a crucial factor for the potential development of generic versions of the drug.
How does Delstrigo compare to other HIV medications?
Delstrigo is one of many combination antiretroviral therapies available for HIV treatment. Other regimens may involve different combinations of drugs or different classes of antiretrovirals. The choice of HIV medication is highly individualized and depends on various factors, including viral load, CD4 count, patient history, potential drug interactions, and tolerability [1].
What are the clinical trial results for Delstrigo?
Clinical trials have demonstrated the efficacy of Delstrigo in achieving and maintaining viral suppression in adults with HIV-1 infection. Studies have shown that Delstrigo is non-inferior to other antiretroviral regimens in terms of viral load reduction [1].
What should patients consider before starting Delstrigo?
Before starting Delstrigo, patients should inform their healthcare provider about all their medical conditions, including any kidney problems, liver problems, or heart conditions. They should also list all medications, supplements, and herbal products they are taking, as Delstrigo can interact with certain drugs [1].
---
Sources:
1. https://www.delstrigo.com/
2. https://drugpatentwatch.com/